Comparison of levosimendan and nitroglycerine in patients undergoing coronary artery bypass graft surgery

Manoj K. Sahu, Anupam Das, Vishwas Malik¹, Arun Subramanian¹, Sarvesh Pal Singh, Milind Hote
Departments of Cardiothoracic and Vascular Surgery and ¹Cardiac Anaesthesia, All India Institute of Medical Sciences, New Delhi, India

ABSTRACT

Background: Levosimendan a calcium ion sensitizer improves both systolic and diastolic functions. This novel lusitropic drug has predictable antiischemic properties which are mediated via the opening of mitochondrial adenosine triphosphate-sensitive potassium channels. This action of levosimendan is beneficial in cardiac surgical patients as it improves myocardial contractility, decreases systemic vascular resistance (SVR), and increases cardiac index (CI) and is thought to be cardioprotective. We decided to study whether levosimendan has any impact on the outcomes such as the duration of ventilation, the length of Intensive Care Unit (ICU) stay, and the hospital stay when compared with the nitroglycerine (NTG), which is the current standard of care at our center. Materials and Methods: Forty-seven patients undergoing elective coronary artery bypass surgery were randomly assigned to two groups receiving either levosimendan or NTG. The medications were started before starting surgery and continued until 24 h in the postoperative period. Baseline hemodynamic parameters were evaluated before beginning of the operation and then postoperatively at 3 different time intervals. N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) levels were also measured in both groups. Results: In comparison to the NTG group, the duration of ventilation and length of ICU stay were significantly less in levosimendan group (P < 0.05, P = 0.02). NT-proBNP level analysis showed a slow rising pattern in both groups and a statistically significant rise in the levels was observed in NTG group (P = 0.03, P = 0.02) in postoperative period when compared to levosimendan group of patients. Conclusion: Levosimendan treatment in patients undergoing surgical revascularization resulted in improved CI, decreased SVR and lower heart rate. And, thereby the duration of ventilation and length of ICU stay were significantly less in this group of patients when compared with NTG group.

Key words: Coronary artery bypass; Levosimendan; Nitroglycerine; Pro brain natriuretic peptide

INTRODUCTION

Myocardial dysfunction, a frequent complication after open heart surgeries performed under cardiopulmonary bypass (CPB) is mediated by ischemia and reperfusion injuries. Myocardial preservation with cold primed potassium rich cardioplegia prevents ischemia by causing electromechanical arrest of the heart in diastole and by reducing the myocardial oxygen consumption. However, many patients still develop myocardial dysfunction requiring pharmacological or mechanical circulatory support during weaning off CPB and/or afterward in the postoperative period in the Intensive Care Unit (ICU), accounting for increased morbidity and mortality.[¹,²]

Address for correspondence: Dr. Manoj K. Sahu, Department of Cardiothoracic and Vascular Surgery, CTVS Office, 7th Floor, CN Centre, All India Institute of Medical Sciences, New Delhi - 110 029, India. E-mail: drmanojsahu@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Sahu MK, Das A, Malik V, Subramanian A, Singh SP, Hote M. Comparison of levosimendan and nitroglycerine in patients undergoing coronary artery bypass graft surgery. Ann Card Anaesth 2016;19:52-8.
Levosimendan, a calcium ion sensitizer with a unique mechanism of action has been used in patients with poor left ventricular function undergoing coronary revascularization and in acute heart failure situations.\textsuperscript{[3,4]} It has a positive inotropic\textsuperscript{[5]} and anti-stunning effects mediated by calcium sensitization of contractile proteins.\textsuperscript{[6]} By opening of the adenosine triphosphate (ATP)-sensitive potassium (K-ATP) channels, levosimendan imparts additional vasodilatory\textsuperscript{[7]} and anti-ischemic properties.\textsuperscript{[8]} The K-ATP channel being an important mediator of cardioprotection,\textsuperscript{[8]} levosimendan may offer beneficial effect in situations of myocardial stress.

NTG has been in use in the patients undergoing surgical coronary revascularization since long with proven benefits.\textsuperscript{[9]} However, its effect is not predictable when used as an infusion for a longer period of time due to tachyphylaxis.\textsuperscript{[10]} Further, additional inotropic support is required in many patients in the immediate postoperative period.

**MATERIALS AND METHODS**

Following approval of Hospital Research Ethics Committee and obtaining written informed consent, 47 adult patients undergoing elective on-pump coronary artery bypass graft surgery (CABG) were enrolled for this study. The patients were randomly allocated to levosimendan (Group L) (Simenda Injection Manufactured by Lupin Ltd. India) and nitroglycerine (NTG) (NTG Injection Manufactured by Unimed Technologies Ltd. India) (Group N) groups. This study was conducted in Cardiothoracic and Vascular Surgery operating room and ICU, All India Institute of Medical Sciences between January 2013 and January 2014. Inclusion criteria were age >18 years and normal ejection fraction (ejection fraction >50%) undergoing 1\textsuperscript{st} time on pump CABG. Exclusion criteria included cardiac failure, unstable angina, associated valvular heart disease, diabetes mellitus treated with sulfonylureas, renal dysfunction (preoperative serum creatinine >1.5 mg/dl), abnormal liver function (serum aspartate aminotransferase or alanine aminotransferase >100 IU/L) and significant chronic obstructive pulmonary disease (forced expiratory volume in 1 s <50% of the predicted value or <2 L), history of prior CABG or recent MI within the previous month.

In the operation theater, patients were monitored with electrocardiogram, invasive blood pressure, pulse oximetry, nasopharyngeal temperature, pulmonary artery catheter (PAC), arterial blood gas, urine output, and capnography. The mean arterial pressure (MAP) and heart rate (HR) were maintained at 80–100 mmHg and 60–80/min respectively in both the groups at all points of time prior to initiation of CPB. After the induction of anesthesia and tracheal intubation, a continuous thermodilution PAC (CCO-PAC, Edwards Lifesciences, Irvine, CA, USA) was inserted in the right internal jugular vein under sterile conditions and the baseline hemodynamic data such as cardiac index (CI), systemic vascular resistance (SVR), and pulmonary capillary wedge pressure (PCWP) were recorded. The aim was to maintain the CI, SVR, and PCWP near normal at all points of time. The study drug levosimendan or NTG was administered as a slow intravenous (iv) infusion through the central venous port of a PAC before starting the operation. Hypotension, defined as MAP <60 mm Hg was treated by iv fluid or phentylephrine boluses of 50 μg, similarly, hypertension was treated with boluses of fentanyl, midazolam or metoprolol. As per the standard protocol, CPB was established after systemic heparinization and coronary artery bypass operation was performed under mild hypothermia (32°C) using one left internal mammary artery (LIMA) and one to three vein grafts obtained from lower limbs. CPB was discontinued following rewarming up to 36°C of nasopharyngeal temperature. After surgery, all patients were shifted to ICU and electively ventilated and sedated with propofol infusion at 1 mg/kg/h. Upon meeting the extubation criteria (CI >2.5 L/min/m\textsuperscript{2}, hemodynamic stability, no significant arrhythmias, hemoglobin >10 g/dl, no signs of excessive bleeding (>100 ml/h), peripheral temperature exceeded 33°C, urine output >0.5 ml/kg/h, adequate response to command, arterial oxygen saturation by pulse oximetry [SpO\textsubscript{2}] >95% at a fraction of inspired oxygen concentration [FiO\textsubscript{2}] <0.6, pH >7.3, arterial carbon dioxide tension [PaCO\textsubscript{2}] <40 mm Hg and adequate respiratory effort) the patients were extubated.

The patients were shifted to the wards when they fulfilled the following eligibility criteria SpO\textsubscript{2} >95% at a FiO\textsubscript{2} <0.5 by face mask, adequate hemodynamic stability with no arrhythmias, chest tube drainage <50 ml/h, urine output >0.5 ml/kg/h, and no inotropic or vasopressor therapy. The criteria for discharging the patients from hospital were hemodynamic stability without arrhythmias, the presence of clean, dry wounds, no pyrexia, and no difficulty in bowel and bladder movements, ambulating and eating independently.
Drug administration

The study drug levosimendan was started at 10 mcg/kg over 10 min as a loading dose through CCO-PAC followed by an infusion at 0.1 mcg/kg/min in Group L and continued up to 24 h in the ICU. Similarly, in Group N, NTG was started at 0.5 mcg/kg/min. The drugs were started prior to skin incision after the baseline hemodynamic parameters were recorded from PAC and continued post-CPB in the ICU for 24 h. Post-CPB in odds ratio and in the ICU inotropic support epinephrine infusion at 0.05–0.1 mcg/kg/min was commenced if MAP <65 mm Hg with CI <2 L in the presence of PCWP of 15 and HR of 70–110 in NTG group and norepinephrine infusion at 0.05–0.1 mcg/kg/min was used for MAP <65, SVR <800 dynes/s/cm⁻5 and a CI >3l/m²/min in Group L. Seven patients from Group N and 10 patients from Group L received epinephrine and norepinephrine infusions, respectively, and all these patients (n = 17) were excluded from the study [Figure 1].

Blood samples for an N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) levels were drawn in ethylenediaminetetraacetic acid vials and were estimated at 3 different time points by immunoassay (Alere Triage R NT-proBNP kits, Alere Inc. Waltham, MA, USA). T1 was before starting the study drugs, T2 at 12 h and T3 at 24 h post CABG in the ICU. Hemodynamic measures were recorded at 4 different time points, before starting the study drugs (T1), at 6 h (T2), at 12 h (T3), and at 24 h (T4) in the ICU.

Outcomes

The outcomes such as duration of ventilation, the length of ICU stay, and the length of hospital stay were observed in this study.

Analysis

Patient demographics, hemodynamics, and NT-proBNP levels were reported as mean ± standard deviation. The above data were analyzed by independent Student’s t-test between two groups, whereas repeated measures analysis was done with paired samples t-test to compare the values within the same group at 4 different time points. All the categorical variables were analyzed using Fisher’s exact test. P < 0.05 was considered statistically significant. All the data were analyzed by SPSS version 21.0 (IBM SPSS Statistics, Version 21.0. Armonk, NY: IBM Corp. USA).

RESULTS

In this study, we enrolled 47 consecutive patients divided into two groups - Group L (n = 25) and Group N (n = 22). After excluding, 17 patients who required inotropes and vasopressors [Figure 1] (seven from NTG group and 10 from levosimendan group), each group had 15 patients. The data from all 30 patients were included in the statistical analysis. The two groups were comparable with respect to demographic and intraoperative data [Table 1]. No significant difference was observed in CPB time, aortic cross-clamp time and number of vessels grafted [Table 1].

Table 2 summarizes postoperative results and clinical outcomes. The length of ICU stay and duration of ventilation were significantly less in Group L (P = 0.02 and P < 0.05). However, there was no difference in hospital stay between both groups [Table 2].

Table 3 shows hemodynamic variables (HR, MAP, PCWP, CI, and SVR) measured at various time intervals in both groups. No significant difference in baseline hemodynamic values was seen between the groups [Table 3]. The CI measured at T2, T3, and T4 after surgery was significantly higher in Group L (P = 0.03, P = 0.02, P < 0.05) [Table 3] and SVR measured at T2 and T3 were significantly lower in Group L (P = 0.02, P = 0.04) [Table 3] when compared with the values at same time points in Group N. And also there was significant decrease in SVR at T2, T3, and T4 compared with the T1 values within both groups individually [Table 3]. The CI was significantly higher at T4 when compared to T1 in both groups independently [Table 3].

Table 4 depicts the NT-proBNP levels in both groups. The NT-proBNP levels rose in both the groups post-CPB but the rate of rise was statistically significant in
Group N ($P = 0.03, P = 0.02$) when compared with Group L. The rise of NT-proBNP within the Group L was less than the rise within the N group ($P = 0.02, P = 0.04$).

There were no postoperative adverse cardiovascular events/complications such as myocardial infarction, life-threatening arrhythmias, pulmonary edema, and major neurological deficit in both groups. Intra-aortic balloon counterpulsation was not required for any of the patients in both groups. Re-exploration for significant postoperative bleeding was performed in two patients (one in each group) [Table 2].

**DISCUSSION**

In this study, we have shown that levosimendan may be superior to NTG as far as left ventricular systolic and diastolic functions (significant increase in postoperative CI, a decrease in SVR, lower HR, and less rise in NT-proBNP levels in Group L when compared to Group N) are concerned. This could be seen from a significant reduction in ventilation duration, the length of ICU stay and earlier extubation in Group L.

Despite the use of contemporary cardioprotective strategies, variable degrees of myocardial stunning occur after cardiac surgery, and this may result in postoperative myocardial dysfunction. Myocardial stunning represents a prolonged posts ischemic contractile dysfunction of myocardium salvaged by reperfusion. Studies have demonstrated contractile dysfunction over first few hours after myocardial revascularization that generally resolves spontaneously over 24–48 h. During the period of transient myocardial dysfunction, there is a need to improve the myocardial function, so inotropic agents are chosen for hemodynamic support. Unlike regularly used inotropes, levosimendan improves myocardial contractility primarily by enhancing myocardial contractile protein sensitivity to calcium without increasing its intracellular concentration. This

---

Table 1: Baseline demographic and surgical data in both groups

| Parameters          | Group L (n=15) | Group N (n=15) | P value |
|---------------------|---------------|----------------|---------|
| Age (yr)            | 63±11.31      | 61±12.17       | 0.72    |
| Sex                 | 10            | 11             | 0.50    |
| Weight (Kg)         | 74±9.0        | 75±13.0        | 0.57    |
| Height (cm)         | 165.9±8.3     | 166.4±7.9      | 0.90    |
| Ejection fraction%  | 57±3.5        | 56.8±2.0       | 0.80    |
| CPB duration (min)  | 75.8±6.5      | 75.5±6.4       | 0.71    |
| ACC duration (min)  | 47.5±8.8      | 46.7±5.5       | 0.87    |
| Number of grafts    | 3±1           | 3±1            | 0.92    |

CPB: Cardiopulmonary bypass, ACC: Aortic cross clamp

Table 2: Post-operative results: Data expressed as mean±standard deviation

| Parameters          | Group L (n=15) | Group N (n=15) | P value |
|---------------------|---------------|----------------|---------|
| Thirty day mortality| 0             | 0              | >0.05   |
| Ventilation duration (hrs.) | 6.3±1.5  | 8.5±1.8       | <0.05   |
| ICU stay (hrs.)     | 33±7.1        | 43±14.2        | 0.02    |
| Hospital stay (days)| 12.3±1.8      | 12.0±1.7       | 0.77    |
| Re-exploration (n)  | 1             | 1              | >0.05   |

Table 3: Haemodynamic variables at different time intervals (Data expressed as mean±standard deviation)

| Parameters          | Group | T1    | T2    | T3    | T4    |
|---------------------|-------|-------|-------|-------|-------|
| HR (beats/minutes)  | L     | 64±8.2| 69±7.4*| 70±6.6*| 67±8.1|
| P value             |       | 0.97  | 0.001 | 0.002 | <0.001|
| MAP (mmHg)          | L     | 84±5.6| 86±6.5| 83±4.8| 82.9±4.4|
| P value             |       | 0.95  | 0.48  | 0.75  | 0.49   |
| CI (ml/min/square meter) | L     | 3.1±0.7| 3.2±0.7| 3.3±0.7| 3.4±0.5*|
| PCWP (mmHg)         | L     | 1221±390.1| 1116±318.1*| 1116±318.1*| 1101.9±307.1*|
| P value             |       | 0.06  | 0.02* | 0.04* | 0.10   |
| SVR (mmHg)          | L     | 1489±383.4| 1391±361.2*| 1369±350.2*| 1277±311.1*|
| P value             |       | 0.29  | 0.82  | 0.13  | 0.82   |

HR: Heart rate, MAP: Mean arterial pressure, CI: Cardiac index, SVR: Systemic vascular resistance, PCWP: Pulmonary capillary wedge pressure; *P<0.05 between T1 and T2 within the group; **P<0.05 between T1 and T3 within the group; ***P<0.05 between T1 and T4 within the group; *P<0.05 between the two groups.
Levosimendan acts by direct binding with protein-C, thereby increasing the affinity of troponin-C for calcium. A lack of calcium sensitization under low calcium concentration (i.e., during diastole) has been shown to prevent worsening of diastolic dysfunction in patients with heart failure. Levosimendan causes vasodilation, which has been attributed to activation of K-ATP channels and decreasing the sensitivity to calcium. An increase in coronary blood flow and reduction in coronary vascular resistance have been reported.

Many studies have indicated that early use of levosimendan induces protection against subsequent ischemic stress through its K-ATP channel opening properties. The opening and stimulation of mitochondrial K-ATP channel are an important mediator which protects the heart against ischemia-reperfusion damage, decreasing myocardial infarct size, does ischemic preconditioning, and enhances recovery of stunned myocardium. Clinical use of levosimendan has shown to improve cardiac performance in left ventricular failure.

Our study confirmed the benefits of the early use of levosimendan in on-pump CABG patients by improving the hemodynamics and maintaining a steady level of NT-proBNP and with this the outcome advantages (reduced length of ICU stay). Our findings are similar to the results observed in recent studies, strengthening the conclusion that the observed increase in CI produced by levosimendan probably the result of combined action of reduced SVR (LV afterload) and a modest increase in myocardial contractility. Levosimendan has a fast onset of action (due to short elimination half-life of 1 h) but its effects are long lasting due to its active metabolite OR-1896 (has a long elimination half-life of 70–80 h). This long half-life of OR-1896 maintains the drug’s efficacy for up to 9 days after 24 h infusion. This along with its less arrhythmogenic property makes it superior over other traditional inotropes. Data suggest that this effect might be related to anti-inflammatory and anti-apoptotic properties. Owing to its K-ATP channel opening properties, levosimendan produces vasodilatation and causes potentially significant hypotension. Use of nor-epinephrine (as a vasoconstrictor) infusion has been recommended in many studies to counter the hypotension induced by levosimendan.

Despite the proven benefit of NTG after CABG, it has got its own limitations, of which tolerance is most important. The mechanism of tolerance has been extensively investigated. To overcome this disadvantage, we compared NTG with levosimendan to assess the later’s efficacy as a lusitropic agent and thereby making it an alternative to NTG in patients undergoing on-pump CABG. Kivikko et al. in their review opined that tolerance was absent with levosimendan, despite 48 h of infusion and that the cardiac performance improved with no increase in oxygen consumption. Another theoretical possible disadvantage of application of NTG is that it can affect pulmonary gas exchange in the early postoperative period by stealing the pulmonary blood flow to areas of less ventilation (antagonizing effect on hypoxic pulmonary vasoconstriction). This is particularly seen after on-pump cardiac surgeries where early postoperative hypoxemia is not uncommon. Because of this, the time on tracheal intubation gets prolonged, and ICU stay becomes longer. Moreover, the third disadvantage with NTG is that it is purely a vasodilator having no inotropic action. In early postoperative period due to the myocardial contractile dysfunction, some amount of inotropic support is required alongside with NTG for the heart to recover from myocardial stunning effect. NTG has advantages in early postoperative period because of its antihypertensive action (as vasoconstriction plays a major role in causing hypertension). NTG, a coronary vasodilator, prevents spasm of LIMA, and it helps in uniform rewarming of the patient before terminating the CPB. Despite all these advantages, we in the current study could demonstrate that NTG is inferior to levosimendan in patients undergoing on-pump CABG. The hemodynamics (higher CI, lower SVR, and lower HR) were better maintained with levosimendan than NTG and the outcomes such as ventilation duration and length of ICU stay were shorter with levosimendan. Adrenaline was used as inotrope at 0.05 mcg/kg/min by other studies to support the MAP if it decreases while the patient is on NTG infusion.
NT-proBNP has been used as one of the biochemical markers for risk stratification with coronary artery disease.[28] NT-proBNP reliably detects both systolic and diastolic dysfunction in patients undergoing CABG under CPB.[29] Since the rise of NT-proBNP levels was less in Group L, it was justified to say that levosimendan had a beneficial effect on both systolic and diastolic function which was correlated clinically from improved hemodynamic parameters such as increased CI and decreased SVR. Though NT-proBNP levels were expected to fall 24 h postsurgery, the biochemical picture was opposite. The half-life of NT-proBNP is considered to be 60–120 min.[30] suggesting that meaningful changes in hemodynamics could be reflected by this test theoretically every 12 h. Thus, NT-proBNP concentrations lag behind the clinical picture, given its longer time for clearance.

**CONCLUSION**

Early treatment with levosimendan (before skin incision) with bolus and then continuous infusion in patients undergoing on-pump CABG surgery resulted in earlier extubation, reduction in ventilation duration and a shorter length of ICU stay. Thus levosimendan can be used as an alternative to routine NTG, though at a higher cost. More studies are required to find out if the same beneficial clinical outcomes are achieved in patients undergoing high-risk cardiac surgery.

**Limitations**

The current study has a small sample size. A bigger sample size is necessary to prove the superiority of levosimendan over NTG. Echocardiographic evaluation in postoperative period could have been done to assess the systolic and diastolic functions. Other biochemical markers could have been tested to detect any myocardial injury/or any new onset of myocardial ischemia/infarction.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Christakis GT, Fremes SE, Naylor CD, Chen E, Rao V, Goldman BS. Impact of preoperative risk and perioperative morbidity on ICU stay following coronary bypass surgery. Cardiovasc Surg 1996;4:29-35.
2. Loop FD, Higgins TL, Panda R, Pearce G, Estafanos FG. Myocardial protection during cardiopulmonary bypass grafting with cardiopulmonary bypass. J Thorac Cardiov Surg 1992;104:608-18.
3. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012;17:125-30.
4. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009;102:198-204.
5. De Hert SG, Lorsomræde S, Cromheecke S, van der Linden Pj. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104:766-73.
6. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556-69.
7. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-9.
8. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: Preclinical and clinical evidence. J Cardiovasc Pharmacol 2007;50:257-63.
9. Lavine SJ, Campbell CA, Held AC, Johnson V. Effect of nitroglycerin-induced reduction of left ventricular filling pressure on diastolic filling in acute dilated heart failure. J Am Coll Cardiol 1989;14:233-4.
10. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000;102:2810-5.
11. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SR. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56:978-85.
12. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, et al. Acute myocardial dysfunction and recovery: A common occurrence after coronary bypass surgery. J Am Coll Cardiol 1990;15:1261-9.
13. Ukkonen H, Saraste M, Akkila J, Knuuti MJ, Leihokainen P, Nägren K, et al. Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997;61:996-107.
14. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-31.
15. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca++ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59.
16. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in...
coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-25.
17. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-9.
18. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: The role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta 2003;1606:1-21.
19. Kersten JR, Montgomery MW, Pagel PS, Wartnier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11.
20. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting – A pilot study. Br J Anaesth 2006;96:694-700.
21. Auchampach JA, Maruyama M, Caverio I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992;86:311-9.
22. De Santis V, Vitale D, Tritapepe L, Greco C, Pietropaoli P. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med 2008;149:365-7.
23. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007;35:2732-9.
24. McLean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 2005;46:830-5.
25. Kivikkö M, Antila S, Eha J, Lehtonen L, Pentikiiinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002;42:43-51.
26. Masoumi G, Pour EH, Sadeghpour A, Ziaeeefard M, Alavi M, Anbardan SJ, et al. Effect of different dosages of nitroglycerin infusion on arterial blood gas tensions in patients undergoing on-pump coronary artery bypass graft surgery. J Res Med Sci 2012;17:123-7.
27. Masoumi G, Hidarpour E, Tabae AS, Ziaeeefard M, Azarasa A, Abneshahidi A, et al. Evaluating hemodynamic outcomes of different dosages of intravenous nitroglycerin after coronary artery bypass graft surgery. J Res Med Sci 2011;16:910-5.
28. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40.
29. Faida O, Said A, Samir P, Car D, Oteh M, Latif MA, et al. Nt-proBNP levels, as predictor of left ventricular systolic and diastolic dysfunction in patients with chronic heart failure. Int J Collab Res Intern Med Public Health 2012;4:910-23.
30. Hammer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: New laboratory parameters in heart failure patients. Clin Lab 2001;47:265-77.